GlassScriptPhysician profile
Andrew J Norris
NPI 1780031971
$1,235.77
in general payments reported to CMS, 2019-2025
18 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.25 · 2022: $258 · 2023: $252 · 2024: $481 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $237.08 | 2021-2024 | Tavneos, Krystexxa, Parsabiv |
| Nxstage Medical, INC. | $197.38 | 2022-2024 | |
| Glaxosmithkline, LLC. | $116.71 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $109.26 | 2023-2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $97.92 | 2022-2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $92.16 | 2023-2025 | Farxiga |
| Vifor Pharma, INC. | $86.44 | 2023-2024 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.66 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $41.34 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.72 | 2023-2025 | |
| Baxter Healthcare | $26.59 | 2024 | |
| Ardelyx, INC. | $23.15 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $21.79 | 2024 | |
| Exact Sciences Corporation | $19.96 | 2023 | Cologuard Collection Kit |
| Travere Therapeutics, INC. | $19.42 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.85 | 2023 | Givlaari |
| Novo Nordisk INC | $18.83 | 2023 | Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $13.51 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.